NASDAQ: SRZNW - Surrozen Inc. Warrant

Rentabilität für sechs Monate: +43.36%
Dividendenrendite: 0.00%

Aktionsplan Surrozen Inc. Warrant

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Surrozen Inc. Warrant

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis.

weitere details
The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2021-08-12
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.surrozen.com
Цена ао 0.0252
Preisänderung pro Tag: -22.86% (0.021)
Preisänderung pro Woche: -22.86% (0.021)
Preisänderung pro Monat: -66.8% (0.0488)
Preisänderung über 3 Monate: -58.46% (0.039)
Preisänderung über sechs Monate: +43.36% (0.0113)
Preisänderung pro Jahr: -19% (0.02)
Preisänderung seit Jahresbeginn: -42.35% (0.0281)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Gesamt: 2.5

Effizienz

Name Bedeutung Grad
ROA, % 0 0
ROE, % 0 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 80.22 9
Rentabilität EPS, % -65.57 0
Gesamt: 5.2
Weitere Details

Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Craig C. Parker M.B.A. CEO, President & Director 1962 (63 Jahr)
Mr. Charles Williams CFO, COO & Corporate Secretary 1980 (45 Jahre)
Dr. Li Yang Ph.D. Executive Vice President of Research 1969 (56 Jahre)
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board
Dr. Roeland Nusse Ph.D. Co-Founder & Member of Scientific Advisory Board 1950 (75 Jahre)
Dr. Calvin Kuo M.D., Ph.D. Co-Founder & Member of Scientific Advisor
Esther Jhun Controller

Adresse: United States, South San Francisco, 171 Oyster Point Boulevard - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.surrozen.com